Navigation Links
Advance in Bowel Cancer Test Research
Date:6/3/2009

SYDNEY, June 3 /PRNewswire/ -- Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls.

Being presented today at the Digestive Disease Week conference in Chicago, the preliminary findings are the result of a collaborative study - involving CSIRO, Flinders University and Australian healthcare company, Clinical Genomics Pty Ltd - designed to develop an improved screening/diagnostic test for detecting bowel cancer and significant pre-cancer lesions.

"If we can now show that the levels of these biomarkers in blood or stool also correlate strongly with disease state in a large group of patients with cancer or pre-cancer lesions (ie adenomatous polyps) we may have the basis for a very important new diagnostic weapon in the fight against bowel cancer," says CSIRO's Preventative Health National Research Flagship Theme Leader in Colorectal Cancer and Gut Health, Dr Trevor Lockett.

According to Professor Graeme Young from Flinders University's Centre for Cancer Prevention and Control, regular screening for bowel cancer in people aged 50 years and over is a powerful tool for reducing the impact of the disease in Australia.

"If we can develop a screening test that can point to the presence of clinically important pre-cancerous adenomas which are then removed during follow-up colonoscopy, we will actually be able to prevent the occurrence of bowel cancer in some cases," Professor Young says.

The CEO of Clinical Genomics Pty Ltd, Lawrence La Pointe, says if a more robust screening test for bowel cancer and especially pre-cancer lesions emerges, the research team will have achieved a major advance likely to further improve screening outcomes and more precisely identify those people most likely to benefit from colonoscopic investigation.

Digestive Diseases Week is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Image available at:

Further Information:

    Dr Trevor Lockett, Preventative Health Flagship
    Ph: +61 2 9490 5140
    E: trevor.lockett@csiro.au
    Mb: +61 417 860 540

    Professor Graeme Young
    Flinders University Centre for Cancer Prevention and Control
    E: graeme.young@flinders.edu.au
    Mb +61 400 995 027

    Lawrence La Pointe
    Clinical Genomics Pty Ltd
    E: larry@clinicalgenomics.com

    Media Assistance:
    Kelly Golding
    Preventative Health National Research Flagship
    Mb: +61 458 503 304
    E: kelly.golding@csiro.au


'/>"/>
SOURCE Clinical Genomics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017  Sysmex America, ... urinalysis diagnostic testing equipment as well as middleware ... a way to make quality assurance easier and ... "Sysmex is well known for the innovation that ... Quality Monitor elevates quality assurance processes to a ...
(Date:7/10/2017)... , July 10, 2017  BDI Group subsidiary ... patient support services organization serving specialty pharmacies, home ... launch of four significant, value-added member programs designed ... better manage reimbursement and improve access and affordability ... therapies. ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, ... awareness for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... of long term skin conditions, including cancer. In the short term, overexposure ...
(Date:7/24/2017)... ... 24, 2017 , ... A CDC study shows that, although people are taking more steps to ... 29), had at least one case of sunburn within the past year. It’s common and ... ignore the issue. However, only recently have people become conscientious of the risks that accompany ...
(Date:7/24/2017)... ... 2017 , ... Anyone who uses scales know they have limits; a small ... that same scale to dispense medication. The first example is an issue of capacity, ... it is important to have the right balance for the process. METTLER TOLEDO’s new ...
(Date:7/24/2017)... OR (PRWEB) , ... July 24, 2017 , ... Sharon ... Climate Change and Your Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked ... the rise of myopia in China. , The article by Zidor Aldama described the ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to report ... invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one of ... Allergan is bringing a newly defined structure to the aesthetics market. Dr. Vitenas ...
Breaking Medicine News(10 mins):